InsidersTradesSigma
Follow the Xenon Pharmaceuticals Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Xenon Pharmaceuticals Inc. has logged 39 public disclosures. Market capitalisation: €5.8bn. The latest transaction was disclosed on 1 September 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Machado, Patrick. The full history is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€104,160
2 ops.
Buy Volume
€1m
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Xenon Pharmaceuticals Inc. Strong Buy (bullish), based on 19 analysts. Average price target: US$81.30.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 September 2026
Declarations39 total
700 shares@ CA$60.9766Common SharesTSXSEDI:4771677
Canonical exit: 26 Nov 2026 (T+90)
6,368 shares@ CA$60.1673Common SharesTSXSEDI:4771676
Canonical exit: 26 Nov 2026 (T+90)
8,000 shares@ CA$64.0550.0059% mcap95.2% of flowCommon SharesTSXSEDI:4764860
Canonical exit: 9 Nov 2026 (T+90)
2,000 sharesCommon SharesTSXSEDI:4764859
Canonical exit: 9 Nov 2026 (T+90)
3,500 shares@ CA$7.384.8% of flowCommon SharesTSXSEDI:4764858
3,500 sharesOptionsTSXSEDI:4764857
1,593 sharesRestricted Share UnitsTSXSEDI:4730770
10,507 sharesOptionsTSXSEDI:4730767
2,645 sharesCommon SharesTSXSEDI:4730761
2,645 sharesRestricted Share UnitsTSXSEDI:4730749
1,593 sharesRestricted Share UnitsTSXSEDI:4730740
10,507 sharesOptionsTSXSEDI:4730737
2,645 sharesCommon SharesTSXSEDI:4730724
Common SharesTSXSEDI:4730722
2,645 sharesRestricted Share UnitsTSXSEDI:4730720
1,190 shares@ US$52.990.0009% mcap100.0% of flowCommonSEC144:0001950047-26-005712
3,750 sharesCommon SharesSEC:0001193125-26-106727:0
3,750 sharesCommon SharesSEC:0001193125-26-106726:0
12,500 sharesCommon SharesSEC:0001193125-26-106724:0
75,000 shares@ US$8.4040.3% of flowCommon SharesSEC:0001193125-26-102666:0
7,500 sharesCommon SharesSEC:0001193125-26-102669:0
7,500 sharesCommon SharesSEC:0001193125-26-102667:0
40,000 shares@ US$7.4918.8% of flowCommon SharesSEC:0001193125-26-001172:0
14,375 shares@ US$45.03100.0% of flowCommon SharesSEC:0001193125-25-313147:0
10,288 shares@ US$3.675.2% of flowCommon SharesSEC:0001209191-22-017341:0
25 of 39 declarations
关于 Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. 是一家专注于神经科学的生物制药公司，在美国纳斯达克（XENE）上市，在不列颠哥伦比亚省温哥华和马萨诸塞州波士顿设有办事处。对于法语投资者而言，Xenon 最好被视为一家临床阶段的生物技术公司，而非成熟的商业制药公司。其既定使命是发现、开发并最终商业化针对未满足重大医疗需求的患者的改变生命的疗法。([investor.xenon-pharma.com](https://investor.xenon-pharma.com/)) 公司植根于离子通道生物学和药物化学，其发现能力建立在通道病遗传学的基础上。这一科学基础塑造了以钾和钠通道调节剂为核心的研发管线。Xenon 的主要资产是 azetukalner，一种新型、选择性 Kv7 钾通道开放剂。它正处于癫痫（包括局灶性发作）的 3 期开发阶段，并正在重度抑郁症和双相情感障碍中进行评估。此外，Xenon 还在推进早期疼痛项目，包括处于 1 期阶段的 Nav1.7 和 Kv7 候选药物。([sec.gov](https://www.sec.gov/Archives/edgar/data/1582313/000095017025058092/xene-2025-ars.pdf)) 从竞争角度来看，Xenon 在中枢神经系统药物开发领域占据了一个有趣的利基市场。其战略是利用差异化的机制来解决高负担的神经和神经精神疾病，这种机制可能支持首创或同类最佳的特性。如果临床数据和监管执行保持强劲，这种专业化可能会带来可观的上涨空间。与此同时，该业务高度集中：公司自己的备案文件强调，它严重依赖 azetukalner，并且仍然面临后期生物技术的典型风险，包括临床失败、入组延迟、监管不确定性和未来的融资需求。([sec.gov](https://www.sec.gov/Archives/edgar/data/1582313/000095017025058092/xene-2025-ars.pdf)) 近期消息是实质性的积极。2026 年 3 月，Xenon 公布了局灶性发作 3 期 X-TOLE2 数据的积极顶线结果。2026 年 4 月，它在美国神经病学学会年会上公布了额外的 3 期和 48 个月长期数据，强化了 azetukalner 的临床叙述。2026 年早些时候，管理层还披露了 716 million 美元的备考现金头寸，包括 ATM 收益，称这笔资金可将现金流维持到 2027 年下半年。([investor.xenon-pharma.com](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-positive-topline-data-phase-3-x-tole2-study?utm_source=openai)) 总的来说，Xenon Pharmaceuticals 是一家在美国纳斯达克上市的专业生物技术公司，拥有专注的神经科学管线、科学差异化的平台以及与 azetukalner 后期临床和监管路径高度相关的近期催化剂概况。([investor.xenon-pharma.com](https://investor.xenon-pharma.com/))
